Biotricity Inc (BTCY) Issues Year-End Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- AppLovin gains market share among e-commerce advertisers
- Wall Street ends higher as investors turn to earnings season
Biotricity Provides Year-End Guidance with Expectations to Meet Analyst Revenue Target and Beating Loss and Margin Targets
June 6, 2024 9:27 AM EDTCompany expects Loss from Operations to decrease by over 40% YoY and Margin Improvement by over 10% YoY
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ: BTCY), a leading Technology-as-a-Service (TaaS) company dedicated to disrupting the healthcare industry with cutting-edge medical and consumer diagnostic solutions, is excited to provide guidance for its upcoming Year-End Results. Biotricity announces expectations to meet analyst revenue target, while beating margin and loss targets.
Revenue Growth is expected to exceed 24% YoYLoss from Operations is expected to decrease by over 40% YoYMargins... More